Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
Search Article 
Advanced search 
  Users Online: 567 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  
Year : 2018  |  Volume : 22  |  Issue : 5  |  Page : 689-695

A review on cardiovascular outcome studies of dipeptidyl peptidase-4 inhibitors

Department of Medical Affairs, Lupin Ltd., Mumbai, Maharashtra, India

Correspondence Address:
Maneesha Khalse
Laxmi Towers C Wing, 5th Floor, Bandra Kurla Complex, Mumbai - 400 051, Maharashtra
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/ijem.IJEM_104_18

Rights and Permissions

The U.S. Food and Drug Administration issued a guidance for pharmaceutical industry defining preapproval and postapproval requirements for the demonstration of cardiovascular (CV) safety for all new medications developed for glycemic management in type 2 diabetes. However, results published from the studies of dipeptidyl peptidase-4 (DPP-4) inhibitors are conflicting with regard to different CV endpoints. Upcoming CV outcome studies perhaps will be able to provide additional insights related to diabetes management and help to provide the answers to some of these concerns. This article provides a brief overview regarding how various CV safety evidence of DPP-4 inhibitor evolved over time that highlights possible implication in clinical practice and translates them into effective diabetes management.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded671    
    Comments [Add]    
    Cited by others 5    

Recommend this journal